| Sellas Life Sciences Group Inc (SLS) | |||
|---|---|---|---|
| 1.46 -0.06 (-3.95%) | 04-26 16:00 | ||
| Open: | 1.53 | Pre. Close: | 1.52 |
| High: | 1.545 | Low: | 1.4217 |
| Volume: | 1,279,322 | Market Cap: | 82(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 2.01 One year: 2.35 |
| Support: | Support1: 1.25 Support2: 0.96 |
| Resistance: | Resistance1: 1.72 Resistance2: 2.01 |
| Pivot: | 1.46  |
| Moving Averages: | MA(5): 1.54  MA(20): 1.40 MA(100): MA(250): 1.27 |
| MACD: | MACD(12,26): 0.10 Signal(12,26,9): 0.10 |
| %K %D: | %K(14,3): 54.61 %D(3): 66.31 |
| RSI: | RSI(14): 57.68 |
| 52-Week: | High: 1.91 Low: 0.5 Change(%): 3.5 |
| Average Vol(K): | 3-Month: 1422 10-Days: 1273 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 1.582 - 1.592 | 1.592 - 1.599 |
| Low: | 1.477 - 1.489 | 1.489 - 1.498 |
| Close: | 1.504 - 1.522 | 1.522 - 1.534 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SLS ] has closed below upper band by 48.6%. Bollinger Bands are 27% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
| Company profile |
|---|
| SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Neutral |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Capital Market | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | 56.27 |
| Shares Float (M) | 55.63 |
| % Held by Insiders | 0.50 |
| % Held by Institutions | 10.47 |
| Shares Short (K) | 5270 |
| Shares Short Prior Month (K) | 4510 |
| Stock Financials | |
|---|---|
| EPS | -1.340 |
| Book Value (p.s.) | -0.250 |
| Profit Margin | |
| Operating Margin | |
| Return on Assets (ttm) | -174.3 |
| Return on Equity (ttm) | |
| Qtrly Rev. Growth | |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | |
| Operating Cash Flow (M) | -31.41 |
| Levered Free Cash Flow (M) | -29.64 |
| Stock Valuation | |
|---|---|
| PE Ratio | -1.09 |
| PEG Ratio | |
| Price to Book value | -5.84 |
| Price to Sales | |
| Price to Cash Flow | -2.62 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | |
